智通财经APP获悉，银诺医药-B(02591)午后跌超7%，低见12.33港元，创上市新低，截至发稿，跌6.16%，报12.49港元，成交额1102.07万港元。
消息面上，银诺医药年度业绩显示，营业收入1.32亿元人民币，净亏损3.41亿元 ，亏损同比扩大95.41%。期内研发开支翻倍至2.06亿元。值得注意的是，银诺医药基石投资者的禁售期将于2026年5月14日届满，相关股份将于5月15日正式解禁流通。其中，基石投资者合计持股420.1万股。
智通财经APP获悉，银诺医药-B(02591)午后跌超7%，低见12.33港元，创上市新低，截至发稿，跌6.16%，报12.49港元，成交额1102.07万港元。
消息面上，银诺医药年度业绩显示，营业收入1.32亿元人民币，净亏损3.41亿元 ，亏损同比扩大95.41%。期内研发开支翻倍至2.06亿元。值得注意的是，银诺医药基石投资者的禁售期将于2026年5月14日届满，相关股份将于5月15日正式解禁流通。其中，基石投资者合计持股420.1万股。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.